Myelin

Myelin is a lipid-rich (fatty) substance that surrounds nerve cell axons (the nervous system's "wires") to insulate them and increase the rate at which electrical impulses (called action potentials) are passed along the axon.[1] The myelinated axon can be likened to an electrical wire (the axon) with insulating material (myelin) around it. However, unlike the plastic covering on an electrical wire, myelin does not form a single long sheath over the entire length of the axon. Rather, each myelin sheath insulates the axon over a single long section and, in general, each axon comprises multiple long myelinated sections separated from each other by short gaps called nodes of Ranvier.

Myelin
Structure of simplified neuron in the PNS
Neuron with oligodendrocyte and myelin sheath in the CNS
Details
SystemNervous system
Identifiers
FMA62977
Anatomical terminology

Myelin is formed in the central nervous system (CNS; brain, spinal cord and optic nerve) by glial cells called oligodendrocytes and in the peripheral nervous system (PNS) by glial cells called Schwann cells. In the CNS, axons carry electrical signals from one nerve cell body to another. In the PNS, axons carry signals to muscles and glands or from sensory organs such as the skin. Each myelin sheath is formed by the concentric wrapping of an oligodendrocyte (CNS) or Schwann cell (PNS) process (a limb-like extension from the cell body) around the axon.[2][3] Myelin reduces the capacitance of the axonal membrane. On a molecular level, in the internodes it increases the distance between extracellular and intracellular ions, reducing the accumulation of charges. The discontinuous structure of the myelin sheath results in saltatory conduction, whereby the action potential "jumps" from one node of Ranvier, over a long myelinated stretch of the axon called the internode, before "recharging" at the next node of Ranvier, and so on, until it reaches the axon terminal.[4][5][6] Nodes of Ranvier are the short (c. 1 micron) unmyelinated regions of the axon between adjacent long (c. 0.2 mm – >1 mm) myelinated internodes. Once it reaches the axon terminal, this electrical signal provokes the release of a chemical message or neurotransmitter that binds to receptors on the adjacent post-synaptic cell (e.g., nerve cell in the CNS or muscle cell in the PNS) at specialised regions called synapses.

This "insulating" role for myelin is essential for normal motor function (i.e. movement such as walking), sensory function (e.g. hearing, seeing or feeling the sensation of pain) and cognition (e.g. acquiring and recalling knowledge), as demonstrated by the consequences of disorders that affect it, such as the genetically determined leukodystrophies;[7] the acquired inflammatory demyelinating disorder, multiple sclerosis;[8] and the inflammatory demyelinating peripheral neuropathies.[9] Due to its high prevalence, multiple sclerosis, which specifically affects the central nervous system (brain, spinal cord and optic nerve), is the best known disorder of myelin.

Development
Further information: Critical period § Myelin

The process of generating myelin is called myelination or myelinogenesis. In the CNS, cells called oligodendrocyte precursor cells (OPCs; the precursors of oligodendrocytes) differentiate into mature oligodendrocytes, which form myelin. In humans, myelination begins early in the 3rd trimester,[10] although only little myelin is present in either the CNS or the PNS at the time of birth. During infancy, myelination progresses rapidly, with increasing numbers of axons acquiring myelin sheaths. This corresponds with the development of cognitive and motor skills, including language comprehension, speech acquisition, crawling and walking. Myelination continues through adolescence and early adulthood and although largely complete at this time, myelin sheaths can be added in grey matter regions such as the cerebral cortex, throughout life.[11][12][13]

Species distribution

Myelin is considered a defining characteristic of the jawed vertebrates (gnathostomes), though axons are ensheathed by a type of cell, called glial cells, in invertebrates.[14][15] These glial wraps are quite different from vertebrate compact myelin, formed, as indicated above, by concentric wrapping of the myelinating cell process multiple times around the axon. Myelin was first described in 1854 by Rudolf Virchow,[16] although it was over a century later, following the development of electron microscopy, that its glial cell origin and its ultrastructure became apparent.[17]

In vertebrates, not all axons are myelinated. For example, in the PNS, a large proportion of axons are unmyelinated. Instead, they are ensheathed by non-myelinating Schwann cells known as Remak SCs and arranged in Remak bundles.[18] In the CNS, non-myelinated axons (or intermittently myelinated axons, meaning axons with long non-myelinated regions between myelinated segments) intermingle with myelinated ones and are entwined, at least partially, by the processes of another type of glial cell called the astrocyte.[19]

Composition
Transmission electron micrograph of a cross-section of a myelinated PNS axon, generated at the Electron Microscopy Facility at Trinity College, Hartford, Connecticut
Diagram of a myelinated axon in cross-section
  1. Axon
  2. Nucleus of Schwann cell
  3. Schwann cell
  4. Myelin sheath
  5. Neurilemma

CNS myelin differs slightly in composition and configuration from PNS myelin, but both perform the same "insulating" function (see above). Being rich in lipid, myelin appears white, hence the name given to the "white matter" of the CNS. Both CNS white matter tracts (e.g. the optic nerve, corticospinal tract and corpus callosum) and PNS nerves (e.g. the sciatic nerve and the auditory nerve, which also appear white) each comprise thousands to millions of axons, largely aligned in parallel. Blood vessels provide the route for oxygen and energy substrates such as glucose to reach these fibre tracts, which also contain other cell types including astrocytes and microglia in the CNS and macrophages in the PNS.

In terms of total mass, myelin comprises approximately 40% water; the dry mass comprises between 60% and 75% lipid and between 15% and 25% protein. Protein content includes myelin basic protein (MBP),[20] which is abundant in the CNS where it plays a critical, non-redundant role in formation of compact myelin; myelin oligodendrocyte glycoprotein (MOG),[21] which is specific to the CNS; and proteolipid protein (PLP),[22] which is the most abundant protein in CNS myelin, but only a minor component of PNS myelin. In the PNS, myelin protein zero (MPZ or P0) has a similar role to that of PLP in the CNS in that it is involved in holding together the multiple concentric layers of glial cell membrane that constitute the myelin sheath. The primary lipid of myelin is a glycolipid called galactocerebroside. The intertwining hydrocarbon chains of sphingomyelin strengthen the myelin sheath. Cholesterol is an essential lipid component of myelin, without which myelin fails to form.[23]

Function
Main article: Saltatory conduction
Action potential propagation in myelinated neurons is faster than in unmyelinated neurons because of Saltatory conduction.

The main purpose of myelin is to increase the speed at which electrical impulses propagate along the myelinated fiber. In unmyelinated fibers, electrical impulses (action potentials) travel as continuous waves, but, in myelinated fibers, they "hop" or propagate by saltatory conduction. The latter is markedly faster than the former, at least for axons over a certain diameter. Myelin decreases capacitance and increases electrical resistance across the axonal membrane (the axolemma). It has been suggested that myelin permits larger body size by maintaining agile communication between distant body parts.[14]

Myelinated fibers lack voltage-gated sodium channels along the myelinated internodes, exposing them only at the nodes of Ranvier. Here, they are highly abundant and densely packed.[24] Positively charged sodium ions can enter the axon through these voltage-gated channels, leading to depolarisation of the membrane potential at the node of Ranvier. The resting membrane potential is then rapidly restored due to positively charged potassium ions leaving the axon through potassium channels. The sodium ions inside the axon then diffuse rapidly through the axoplasm (axonal cytoplasm), to the adjacent myelinated internode and ultimately to the next (distal) node of Ranvier, triggering the opening of the voltage gated sodium channels and entry of sodium ions at this site. Although the sodium ions diffuse through the axoplasm rapidly, diffusion is decremental by nature, thus nodes of Ranvier have to be (relatively) closely spaced, to secure action potential propagation.[25] The action potential "recharges" at consecutive nodes of Ranvier as the axolemmal membrane potential depolarises to approximately +35 mV.[24] Along the myelinated internode, energy-dependent sodium/potassium pumps pump the sodium ions back out of the axon and potassium ions back into the axon to restore the balance of ions between the intracellular (inside the cell, i.e. axon in this case) and extracellular (outwith the cell) fluids.

Whilst the role of myelin as an "axonal insulator" is well-established, other functions of myelinating cells are less well known or only recently established. The myelinating cell "sculpts" the underlying axon by promoting the phosphorylation of neurofilaments, thus increasing the diameter or thickness of the axon at the internodal regions; helps cluster molecules on the axolemma (such as voltage-gated sodium channels) at the node of Ranvier;[26] and modulates the transport of cytoskeletal structures and organelles such as mitochondria, along the axon.[27] In 2012, evidence came to light to support a role for the myelinating cell in "feeding" the axon.[28][29] In other words, the myelinating cell seems to act as a local "fueling station" for the axon, which uses a great deal of energy to restore the normal balance of ions between it and its environment,[30][31] following the generation of action potentials.

When a peripheral fiber is severed, the myelin sheath provides a track along which regrowth can occur. However, the myelin layer does not ensure a perfect regeneration of the nerve fiber. Some regenerated nerve fibers do not find the correct muscle fibers, and some damaged motor neurons of the peripheral nervous system die without regrowth. Damage to the myelin sheath and nerve fiber is often associated with increased functional insufficiency.

Unmyelinated fibers and myelinated axons of the mammalian central nervous system do not regenerate.

Some studies have revealed that optic nerve fibers can be regenerated in postnatal rats. This regeneration depends upon two conditions: axonal die-back has to be prevented with appropriate neurotrophic factors, and neurite growth inhibitory components have to be inactivated. These studies may lead to further understanding of nerve fiber regeneration in the central nervous system.

Clinical significance

Demyelination
Further information: Demyelinating disease

Demyelination is the loss of the myelin sheath insulating the nerves, and is the hallmark of some neurodegenerative autoimmune diseases, including multiple sclerosis, acute disseminated encephalomyelitis, neuromyelitis optica, transverse myelitis, chronic inflammatory demyelinating polyneuropathy, Guillain–Barré syndrome, central pontine myelinosis, inherited demyelinating diseases such as leukodystrophy, and Charcot–Marie–Tooth disease. Sufferers of pernicious anaemia can also suffer nerve damage if the condition is not diagnosed quickly. Subacute combined degeneration of spinal cord secondary to pernicious anaemia can lead to slight peripheral nerve damage to severe damage to the central nervous system, affecting speech, balance, and cognitive awareness. When myelin degrades, conduction of signals along the nerve can be impaired or lost, and the nerve eventually withers. A more serious case of myelin deterioration is called Canavan disease.

The immune system may play a role in demyelination associated with such diseases, including inflammation causing demyelination by overproduction of cytokines via upregulation of tumor necrosis factor[32] or interferon.

Symptoms

Demyelination results in diverse symptoms determined by the functions of the affected neurons. It disrupts signals between the brain and other parts of the body; symptoms differ from patient to patient, and have different presentations upon clinical observation and in laboratory studies.

Typical symptoms include blurriness in the central visual field that affects only one eye, may be accompanied by pain upon eye movement, double vision, loss of vision/hearing, odd sensation in legs, arms, chest, or face, such as tingling or numbness (neuropathy), weakness of arms or legs, cognitive disruption, including speech impairment and memory loss, heat sensitivity (symptoms worsen or reappear upon exposure to heat, such as a hot shower), loss of dexterity, difficulty coordinating movement or balance disorder, difficulty controlling bowel movements or urination, fatigue, and tinnitus.[33]

Myelin repair
Further information: Remyelination

Research to repair damaged myelin sheaths is ongoing. Techniques include surgically implanting oligodendrocyte precursor cells in the central nervous system and inducing myelin repair with certain antibodies. While results in mice have been encouraging (via stem cell transplantation), whether this technique can be effective in replacing myelin loss in humans is still unknown.[34] Cholinergic treatments, such as acetylcholinesterase inhibitors (AChEIs), may have beneficial effects on myelination, myelin repair, and myelin integrity. Increasing cholinergic stimulation also may act through subtle trophic effects on brain developmental processes and particularly on oligodendrocytes and the lifelong myelination process they support. Increasing oligodendrocyte cholinergic stimulation, AChEIs, and other cholinergic treatments, such as nicotine, possibly could promote myelination during development and myelin repair in older age.[35] Glycogen synthase kinase 3β inhibitors such as lithium chloride have been found to promote myelination in mice with damaged facial nerves.[36] Cholesterol is a necessary nutrient for the myelin sheath, along with vitamin B12.[37][38]

Dysmyelination

Dysmyelination is characterized by a defective structure and function of myelin sheaths; unlike demyelination, it does not produce lesions. Such defective sheaths often arise from genetic mutations affecting the biosynthesis and formation of myelin. The shiverer mouse represents one animal model of dysmyelination. Human diseases where dysmyelination has been implicated include leukodystrophies (Pelizaeus–Merzbacher disease, Canavan disease, phenylketonuria) and schizophrenia.[39][40][41]

Invertebrate myelin

Functionally equivalent myelin-like sheaths are found in several invertebrate taxa including oligochaetes, penaeids, palaemonids, and calanoids. These myelin-like sheaths share several structural features with the sheaths found in vertebrates including multiplicity of membranes, condensation of membrane, and nodes.[14] However, the nodes in vertebrates are annular; i.e. they encircle the axon. In contrast, nodes found in the sheaths of invertebrates are either annular or fenestrated; i.e. they are restricted to "spots". It is notable that the fastest recorded conduction speed (across both vertebrates and invertebrates) is found in the ensheathed axons of the Kuruma shrimp, an invertebrate,[14] ranging between 90 and 200 m/s[15] (cf. 100–120 m/s for the fastest myelinated vertebrate axon).

gollark: Where n = infinity.
gollark: Which bot? And what is `FALSE`?
gollark: Also, add Rust support!
gollark: I have a better compression algorithm!
gollark: iPhone `x+y=14`

See also

References
  1. Bean, Bruce P. (June 2007). "The action potential in mammalian central neurons". Nature Reviews Neuroscience. 8 (6): 451–465. doi:10.1038/nrn2148. ISSN 1471-0048. PMID 17514198.
  2. Stassart, Ruth M.; Möbius, Wiebke; Nave, Klaus-Armin; Edgar, Julia M. (2018). "The Axon-Myelin Unit in Development and Degenerative Disease". Frontiers in Neuroscience. 12: 467. doi:10.3389/fnins.2018.00467. ISSN 1662-4548. PMC 6050401. PMID 30050403.
  3. Stadelmann, Christine; Timmler, Sebastian; Barrantes-Freer, Alonso; Simons, Mikael (2019-07-01). "Myelin in the Central Nervous System: Structure, Function, and Pathology". Physiological Reviews. 99 (3): 1381–1431. doi:10.1152/physrev.00031.2018. ISSN 1522-1210. PMID 31066630.
  4. Carroll, SL (2017). "The Molecular and Morphologic Structures That Make Saltatory Conduction Possible in Peripheral Nerve". Journal of Neuropathology and Experimental Neurology. 76 (4): 255–257. doi:10.1093/jnen/nlx013. PMID 28340093.
  5. Keizer J, Smith GD, Ponce-Dawson S, Pearson JE (August 1998). "Saltatory propagation of Ca2+ waves by Ca2+ sparks". Biophysical Journal. 75 (2): 595–600. Bibcode:1998BpJ....75..595K. doi:10.1016/S0006-3495(98)77550-2. PMC 1299735. PMID 9675162.
  6. Dawson SP, Keizer J, Pearson JE (May 1999). "Fire-diffuse-fire model of dynamics of intracellular calcium waves". Proceedings of the National Academy of Sciences of the United States of America. 96 (11): 6060–3. Bibcode:1999PNAS...96.6060D. doi:10.1073/pnas.96.11.6060. PMC 26835. PMID 10339541.
  7. van der Knaap MS, Bugiani M (September 2017). "Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms". Acta Neuropathologica. 134 (3): 351–382. doi:10.1007/s00401-017-1739-1. PMC 5563342. PMID 28638987.
  8. Compston A, Coles A (October 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–17. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977.
  9. Lewis RA (October 2017). "Chronic inflammatory demyelinating polyneuropathy". Current Opinion in Neurology. 30 (5): 508–512. doi:10.1097/WCO.0000000000000481. PMID 28763304.
  10. "Pediatric Neurologic Examination Videos & Descriptions: Developmental Anatomy". library.med.utah.edu. Retrieved 2016-08-20.
  11. Swire M, Ffrench-Constant C (May 2018). "Seeing Is Believing: Myelin Dynamics in the Adult CNS". Neuron. 98 (4): 684–686. doi:10.1016/j.neuron.2018.05.005. PMID 29772200.
  12. Hill RA, Li AM, Grutzendler J (May 2018). "Lifelong cortical myelin plasticity and age-related degeneration in the live mammalian brain". Nature Neuroscience. 21 (5): 683–695. doi:10.1038/s41593-018-0120-6. PMC 5920745. PMID 29556031.
  13. Hughes EG, Orthmann-Murphy JL, Langseth AJ, Bergles DE (May 2018). "Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex". Nature Neuroscience. 21 (5): 696–706. doi:10.1038/s41593-018-0121-5. PMC 5920726. PMID 29556025.
  14. Hartline DK (May 2008). "What is myelin?". Neuron Glia Biology. 4 (2): 153–63. doi:10.1017/S1740925X09990263. PMID 19737435.
  15. Salzer JL, Zalc B (October 2016). "Myelination" (PDF). Current Biology. 26 (20): R971–R975. doi:10.1016/j.cub.2016.07.074. PMID 27780071.
  16. Virchow R (1854). "Ueber das ausgebreitete Vorkommen einer dem Nervenmark analogen Substanz in den thierischen Geweben". Archiv für Pathologische Anatomie und Physiologie und für Klinische Medizin (in German). 6 (4): 562–572. doi:10.1007/BF02116709.
  17. Boullerne AI (September 2016). "The history of myelin". Experimental Neurology. 283 (Pt B): 431–445. doi:10.1016/j.expneurol.2016.06.005. PMC 5010938. PMID 27288241.
  18. Monk KR, Feltri ML, Taveggia C (August 2015). "New insights on Schwann cell development". Glia. 63 (8): 1376–1393. doi:10.1002/glia.22852. PMC 4470834. PMID 25921593.
  19. Wang, Doris D.; Bordey, Angélique (11 December 2008). "The astrocyte odyssey". Progress in Neurobiology. 86 (4): 342–367. doi:10.1016/j.pneurobio.2008.09.015. PMC 2613184 – via Elsevier Science Direct.
  20. Steinman L (May 1996). "Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system". Cell. 85 (3): 299–302. doi:10.1016/S0092-8674(00)81107-1. PMID 8616884.
  21. Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S (April 2015). "The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis". Progress in Neurobiology. 127-128: 1–22. doi:10.1016/j.pneurobio.2015.02.003. PMC 4578232. PMID 25802011.
  22. Greer JM, Lees MB (March 2002). "Myelin proteolipid protein--the first 50 years". The International Journal of Biochemistry & Cell Biology. 34 (3): 211–215. doi:10.1016/S1357-2725(01)00136-4. PMID 11849988.
  23. Saher G, Brügger B, Lappe-Siefke C, Möbius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA (April 2005). "High cholesterol level is essential for myelin membrane growth". Nature Neuroscience. 8 (4): 468–475. doi:10.1038/nn1426. PMID 15793579.
  24. Saladin KS (2012). Anatomy & physiology: the unity of form and function (6th ed.). New York, NY: McGraw-Hill.
  25. Raine CS (1999). "Characteristics of Neuroglia". In Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds.). Basic Neurochemistry: Molecular, Cellular and Medical Aspects (6th ed.). Philadelphia: Lippincott-Raven.
  26. Brivio V, Faivre-Sarrailh C, Peles E, Sherman DL, Brophy PJ (April 2017). "Assembly of CNS Nodes of Ranvier in Myelinated Nerves Is Promoted by the Axon Cytoskeleton". Current Biology. 27 (7): 1068–1073. doi:10.1016/j.cub.2017.01.025. PMC 5387178. PMID 28318976.
  27. Stassart RM, Möbius W, Nave KA, Edgar JM (2018). "The Axon-Myelin Unit in Development and Degenerative Disease". Frontiers in Neuroscience. 12: 467. doi:10.3389/fnins.2018.00467. PMC 6050401. PMID 30050403.
  28. Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, Brinkmann BG, Kassmann CM, Tzvetanova ID, Möbius W, Diaz F, Meijer D, Suter U, Hamprecht B, Sereda MW, Moraes CT, Frahm J, Goebbels S, Nave KA (April 2012). "Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity". Nature. 485 (7399): 517–521. Bibcode:2012Natur.485..517F. doi:10.1038/nature11007. PMC 3613737. PMID 22622581.
  29. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, Liu Y, Tsingalia A, Jin L, Zhang PW, Pellerin L, Magistretti PJ, Rothstein JD (July 2012). "Oligodendroglia metabolically support axons and contribute to neurodegeneration". Nature. 487 (7408): 443–448. Bibcode:2012Natur.487..443L. doi:10.1038/nature11314. PMC 3408792. PMID 22801498.
  30. Engl E, Attwell D (August 2015). "Non-signalling energy use in the brain". The Journal of Physiology. 593 (16): 3417–329. doi:10.1113/jphysiol.2014.282517. PMC 4560575. PMID 25639777.
  31. Attwell D, Laughlin SB (October 2001). "An energy budget for signaling in the grey matter of the brain". Journal of Cerebral Blood Flow and Metabolism. 21 (10): 1133–145. doi:10.1097/00004647-200110000-00001. PMID 11598490.
  32. Ledeen RW, Chakraborty G (March 1998). "Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis". Neurochemical Research. 23 (3): 277–289. doi:10.1023/A:1022493013904. PMID 9482240.
  33. Mayo Clinic 2007 and University of Leicester Clinical Studies, 2014
  34. Windrem MS, Nunes MC, Rashbaum WK, Schwartz TH, Goodman RA, McKhann G, Roy NS, Goldman SA (January 2004). "Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain". Nature Medicine. 10 (1): 93–97. doi:10.1038/nm974. PMID 14702638. Lay summary – FuturePundit.
  35. Bartzokis G (August 2007). "Acetylcholinesterase inhibitors may improve myelin integrity". Biological Psychiatry. 62 (4): 294–301. doi:10.1016/j.biopsych.2006.08.020. PMID 17070782.
  36. Makoukji J, Belle M, Meffre D, Stassart R, Grenier J, Shackleford G, Fledrich R, Fonte C, Branchu J, Goulard M, de Waele C, Charbonnier F, Sereda MW, Baulieu EE, Schumacher M, Bernard S, Massaad C (March 2012). "Lithium enhances remyelination of peripheral nerves". Proceedings of the National Academy of Sciences of the United States of America. 109 (10): 3973–3978. Bibcode:2012PNAS..109.3973M. doi:10.1073/pnas.1121367109. PMC 3309729. PMID 22355115.
  37. Petrov AM, Kasimov MR, Zefirov AL (2016). "Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction". Acta Naturae. 8 (1): 58–73. doi:10.32607/20758251-2016-8-1-58-73. PMC 4837572. PMID 27099785.
  38. Miller A, Korem M, Almog R, Galboiz Y (June 2005). "Vitamin B12, demyelination, remyelination and repair in multiple sclerosis". Journal of the Neurological Sciences. 233 (1–2): 93–97. doi:10.1016/j.jns.2005.03.009. PMID 15896807.
  39. Krämer-Albers EM, Gehrig-Burger K, Thiele C, Trotter J, Nave KA (November 2006). "Perturbed interactions of mutant proteolipid protein/DM20 with cholesterol and lipid rafts in oligodendroglia: implications for dysmyelination in spastic paraplegia". The Journal of Neuroscience. 26 (45): 11743–1752. doi:10.1523/JNEUROSCI.3581-06.2006. PMC 6674790. PMID 17093095.
  40. Matalon R, Michals-Matalon K, Surendran S, Tyring SK (2006). Canavan disease: studies on the knockout mouse. Advances in Experimental Medicine and Biology. 576. pp. 77–93, discussion 361–363. doi:10.1007/0-387-30172-0_6. ISBN 978-0-387-30171-6. PMID 16802706.
  41. Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S (August 2007). "Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia". The International Journal of Neuropsychopharmacology. 10 (4): 557–563. doi:10.1017/S1461145706007334. PMID 17291371.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.